CSL Limited - proposed acquisition of Talecris Biotherapeutics Holdings Corp.


  • CSL Limited


  • Talecris Biotherapeutics Holdings Corp.


CSL Limited (CSL) proposes to acquire Talecris Biotherapeutics Holdings Corp. (Talecris)

Market definition

The ACCC considered the proposed acquisition in the context of the Australian national market for the supply of plasma products.

Competition analysis

On 7 November 2008, the ACCC formed the view that the proposed acquisition was unlikely to substantially lessen competition due to the limited overlap between the merger parties in Australia. Post acquisition the merged entity would continue to face effective competition for the supply of imported plasma products from other significant global suppliers.


20/10/2008ACCC commenced review under the Mergers Review Process Guidelines.
03/11/2008Closing date for submissions from relevant parties.
07/11/2008ACCC announced it would not oppose the proposed acquisition.